Proteomic analysis of AML1/RUNX1 mutant complexes
Proteomic analysis of AML1/RUNX1 mutant complexes
批准号:
15591008
负责人:
HARADA Hironori
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Myelodysplastic syndrome(MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. MDS in a subset of patients arise after previous chemotherapy or radiation exposure for other malignancies. As MDS is a heterogeneous disorder, specific gene abnormalities playing a role in the myelodysplastic process have been difficult to identify. In this study, we analyzed the somatic mutations in the AML1/RUNX1 gene, which is a critical regulator of definitive hematopoiesis and the most frequent targets for translocation of acute myeloid leukemia (AML), in patients with MDS. We detected AML1 point mutations in 26 of 110(23.6%) patients with refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEBt) and AML following MDS (defined these categories as MDS/AML). Among 22 patients with radiation-related (including 14 atomic bomb survivors) and/or therapy-related MDS/AML, 11(50%) patients had the AML1 mutations mostly in N-terminal re … More gion. In contrast, 15 of 88(17%) patients with sporadic MDS/AML showed the AML1 mutations equally in both N-terminal and C-terminal region. The MDS/AML patients with AML1 mutations had a significantly worse prognosis than those without AML1 mutations. Most of AML1 mutants lost trans-activation potential, regardless of their DNA binding potential. These data suggested that AML1 point mutation is one of the major driving forces of MDS/AML, and these mutations may represent a distinct clinicopathologic-genetic entity.To clarify mechanisms of the AML1 dysfunctions, we established cell lines stably expressing FLAG-tagged wild-type or mutant AML1 proteins. A complex of transcriptional factors including these AML1 proteins were purified by immunoprecipitation with an anti-FLAG antibody, and then were analyzed by MALDI-TOF/TOF analyzer. We identified CBFβ,ets-1,p300,C/EBPα and GATA-1 in the complex with wild-type AML1 as well as previous studies using different methods. However, other proteins were identified in the complex with mutated-AML1. We have been analyzing the direct binding ability of AML1 to these proteins. Less
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
MDSにおけるAML1/RUNX1遺伝子異常の意義
AML1/RUNX1 基因异常在 MDS 中的意义
DOI:
--
发表时间:
2005
期刊:
血液・腫瘍科 50(1)
影响因子:
--
作者:
[原田浩徳, 原田結花]
通讯作者:
原田結花
Somatic mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Takaku F, et al.eds.
与骨髓增生异常综合征相关的 AML1/RUNX1 基因体细胞突变。
DOI:
--
发表时间:
2005
期刊:
Annual Review of Hematology 2005 (Chugai Igaku-sya, Tokyo)
影响因子:
--
作者:
[Harada H, et al.]
通讯作者:
et al.
Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome
与骨髓增生异常综合征相关的 AML1/RUNX1 基因点突变
DOI:
--
发表时间:
期刊:
Critical Reviews (in press)
影响因子:
--
作者:
[Harada H, Harada Y]
通讯作者:
Harada Y
MDSにおけるAML1/RUNX1変異 Annual Review血液2005
2005 年 MDS 年度血液审查中的 AML1/RUNX1 突变
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[原田浩徳, 原田結花(分担執筆)(高久文麿他編)]
通讯作者:
原田結花(分担執筆)(高久文麿他編)
Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34^<++> cells in patients with myelodysplastic syndrome(MDS) and MDS-acute myeloid leukaemia.
骨髓增生异常综合征(MDS)及MDS-急性髓系白血病患者CD34^<>细胞粒细胞集落刺激因子受体的表达及功能分析。
DOI:
--
发表时间:
2003
期刊:
British Journal of Haematology 121(1)
影响因子:
--
作者:
[Sultana TA, Harada H, Ito K, Tanaka H, Kyo T, Kimura A]
通讯作者:
Kimura A
共 14 条
Molecular mechanisms of myelodysplastic syndromes (MDS) using RUNX1-mutated iPS cells derived from familial MDS patients
-
批准号:24591398
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2012
-
负责人:HARADA Hironori
-
依托单位:
Establishment of new classification in myeloid neoplasms for personalized medicine
-
批准号:21591206
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2009
-
负责人:HARADA Hironori
-
依托单位:
AML1 point mutations play a pivotal role in the pathogenesis of MDS/AML
-
批准号:19591114
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:HARADA Hironori
-
依托单位:
Genetic pathway in molecular pathogenesis of myelodysplastic syndrome
-
批准号:17590998
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2005
-
负责人:HARADA Hironori
-
依托单位:
国内基金
海外基金
登录
查看更多内容
RUNX1通过BMP2/Smad信号轴调控肿瘤相关巨噬细胞M2极化促进膀胱癌进展的机制研究
-
批准号:2026JJ81626
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黎勇林
-
依托单位:
三尖刺血经RUNX1下调CMPK2磷酸化减轻Ox-mtDNA介导的小胶质细胞炎症反应治疗急性缺血性卒中的机制研究
-
批准号:2026JJ82023
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖靓宜
-
依托单位:
USP11/RUNX1正反馈环路抑制免疫原性细胞死亡促进结直肠癌进展的机制研究
-
批准号:JCZRQN202501352
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
化瘀解毒方调控RUNX1介导自噬依赖性NETosis改善急性脑梗死的机制研究
-
批准号:2025JJ50566
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李定祥
-
依托单位:
RUNX1 正向调控 CCL1-CCR8 轴诱导 ILC2 活化参与过敏性哮喘机制研究
-
批准号:2025JJ60715
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:蒋媛媛
-
依托单位:
RUNX1调控巨噬细胞M1极化及重编程促进糖尿病肾脏病进展的作用及分子机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:关美萍
-
依托单位:
基于RUNX1/RIP3MLKL内源性程序性坏死途径研究消瘤藤总善豆素抵抗肺癌EGFR-TKI耐药的作用机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:黎疆
-
依托单位:
功能性子宫内膜类器官靶向RUNX1调控TGF β1/SMAD3通路促进宫腔粘
连再生修复的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
转录因子RUNX1调控代谢重编程增强脂质合成促进肾透明细胞癌进展的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:30.0万元
-
批准年份:2024
-
负责人:邓煜麟
-
依托单位:
LINC02820介导RUNX1可变剪切增敏TNF/NF-κB信号促进食管鳞癌转移及免疫逃逸
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:黄必军
-
依托单位: